[1] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
[2] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5
[3] Borobia AM, Carcas AJ, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv. Published online May 6, 2020:2020.04.29.20080853. doi:10.1101/2020.04.29.20080853
[4] Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan X-G. Bacterial and fungal infections in COVID-19 patients: A matter of concern. Infect Control Hosp Epidemiol.:1. doi:10.1017/ICE.2020.156
[5] Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. Published online May 2, 2020. doi:10.1093/cid/ciaa530
[6] Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 0(0). doi:10.1016/J.JINF.2020.05.046
[7] Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-332. doi:10.1016/j.ajic.2008.03.002
[8] Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x
[9] Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi:10.1001/jama.2020.5394
[10] Grasselli G, Greco M, Zanella A, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. Published online July 15, 2020. doi:10.1001/jamainternmed.2020.3539
[11] Ferrando C, Mellado-Artigas R, Gea A, et al. Características, evolución clínica y factores asociados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohorte y multi-céntrico. Rev Esp Anestesiol Reanim. Published online July 13, 2020. doi:10.1016/J.REDAR.2020.07.003
[12] Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;0(0). doi:10.1016/j.cmi.2020.07.016
[13] Kreitmann L, Monard C, Dauwalder O, Simon M, Argaud L. Early bacterial co-infection in ARDS related to COVID-19. Intensive Care Med. Published online July 13, 2020:1-3. doi:10.1007/s00134-020-06165-5
[14] Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. J Infect. Published online June 25, 2020. doi:10.1016/j.jinf.2020.06.056
[15] Dudoignon E, Caméléna F, Deniau B, et al. Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series. Clin Infect Dis. Published online June 16, 2020. doi:10.1093/cid/ciaa762
[16] Rawson TM, Moore LSP, Zhu N, et al. Reply to Dudoignon et al. Clin Infect Dis. Published online June 16, 2020. doi:10.1093/cid/ciaa767
[17] Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-887. doi:10.1007/s00134-020-06022-5
[18] Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/J.IJANTIMICAG.2020.105949
[19] Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8(5):506-517. doi:10.1016/S2213-2600(20)30161-2
[20] Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. Published online April 2020. doi:10.1016/j.cmi.2020.04.024
[21] Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck. Infect Control Hosp Epidemiol. 2020;41(6):744-745. doi:10.1017/ice.2020.69
[22] WHO Interim Guidance. Clinical management of COVID-19. 27 May. Published 2020. Accessed August 9, 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19
[23] Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484. doi:10.1016/S2665-9913(20)30173-9
[24] Group TRC. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. Published online July 17, 2020:NEJMoa2021436. doi:10.1056/NEJMoa2021436
[25] Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2020;0(0). doi:10.1016/j.cmi.2020.07.041
[26] Papadimitriou-Olivgeris, M., Drougka, E., Fligou, F. et al. Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients. Infection 42, 1013–1022 (2014). doi:10.1007/s15010-014-0678-1
[27] Estudio Nacional de Vigilancia de Infecciòn Nosocomial en Servicios de Medicina Intensiva (ENVIN). Nosocomial infections in Spanish ICU national registry. https://hws.vhebron.net/envin-helics/
[28] Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID‐19. Eur J Clin Invest. Published online August 11, 2020. doi:10.1111/eci.13319
[29] Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet (London, England). 2020;395(10235):1517-1520. doi:10.1016/S0140-6736(20)30920-X
[30] Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. Published online July 28, 2020. doi:10.1093/cid/ciaa1065